MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome

• Published in: International journal of cancer 2009-08, Vol.125 (4), p.968-972
• Main Authors: Andersson, Ulrika, Osterman, Pia, Sjöström, Sara, Johansen, Christoffer, Henriksson, Roger, Brännström, Thomas, Broholm, Helle, Christensen, Helle Collatz, Ahlbom, Anders, Auvinen, Anssi, Feychting, Maria, Lönn, Stefan, Kiuru, Anne, Swerdlow, Anthony, Schoemaker, Minouk, Roos, Göran, Malmer, Beatrice
• Format: Article
• Language: English
• Subjects: Adult; Aged; association study; Biological and medical sciences; brain tumour; Case-Control Studies; case–control study; Female; Genotype; Glioblastoma - genetics; Glioblastoma - therapy; hTERT; Humans; Male; Medical sciences; Medicin och hälsovetenskap; Meningeal Neoplasms - genetics; Meningeal Neoplasms - therapy; Meningioma - genetics; Meningioma - therapy; Middle Aged; Minisatellite Repeats - genetics; Neurology; Prognosis; survival; Telomerase - genetics; Treatment Outcome; Tumors; Tumors of the nervous system. Phacomatoses; United Kingdom; Young Adult
• ISSN: 0020-7136; 1097-0215; 1097-0215
• DOI: 10.1002/ijc.24363

The human telomerase reverse transcriptase (hTERT) gene is upregulated in a majority of malignant tumours. A variable tandem repeat, MNS16A, has been reported to be of functional significance for hTERT expression. Published data on the clinical relevance of MNS16A variants in brain tumours have been contradictory. The present population‐based study in the Nordic countries and the United Kingdom evaluated brain‐tumour risk and survival in relation to MNS16A minisatellite variants in 648 glioma cases, 473 meningioma cases and 1,359 age, sex and geographically matched controls. By PCR‐based genotyping all study subjects with fragments of 240 or 271 bp were judged as having short (S) alleles and subjects with 299 or 331 bp fragments as having long (L) alleles. Relative risk of glioma or meningioma was estimated with logistic regression adjusting for age, sex and country. Overall survival was analysed using Kaplan–Meier estimates and equality of survival distributions using the log‐rank test and Cox proportional hazard ratios. The MNS16A genotype was not associated with risk of occurrence of glioma, glioblastoma (GBM) or meningioma. For GBM there were median survivals of 15.3, 11.0 and 10.7 months for the LL, LS and SS genotypes, respectively; the hazard ratio for having the LS genotype compared with the LL was significantly increased HR 2.44 (1.56–3.82) and having the SS genotype versus the LL was nonsignificantly increased HR 1.46 (0.81–2.61). When comparing the LL versus having one of the potentially functional variants LS and SS, the HR was 2.10 (1.41–3.1). However, functionality was not supported as there was no trend towards increasing HR with number of S alleles. Collected data from our and previous studies regarding both risk and survival for the MNS16A genotypes are contradictory and warrant further investigations. © 2009 UICC